Prostate cancer researchers use liquid biopsy biomarkers to identify disease before surgery

Dr. Thomas Kislinger, a senior scientist at the Princess Margaret Cancer Centre, explains the use of liquid biopsies to identify prostate cancer. #ConquerCancer

 

Dr. Kislinger: So we discovered liquid biopsies using urine that allows us to identify aggressive prostate cancers prior to surgery. So we used targeted proteomics to accurately and precisely to quantify hundreds of proteins in urine samples to develop this liquid biopsy signatures.

We went through two rounds of verification of our liquid biopsies and the first round we had about 80 patients and here we used about 150 proteins that ultimately 34 of these proteins were then moved to a second independent cord of 210 patients. And then using computational biology, we used the quantitative data that the mass spectrometry provided us for this 34 proteins, to develop this liquid biopsy biomarker for aggressive prostate cancer.

I think we found a better way that allows us to predict which patients have a slow growing, versus an aggressive prostate cancer, in a liquid biopsy in a non-invasive manner and this could then help us to personalize the treatment of these prostate cancer patients. So we're excited about this and the next steps will be a large international study using 1000 urine samples from prostate cancer patients.


To learn more, visit thepmcf.ca